EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA :: NTRK1‐ rearranged soft‐tissue sarcoma cell model

Yanjiang Chen, Sabrina Steiner, Catherine Hagedorn, Sarah Kollar, Alicia Pliego-Mendieta, Martina Haberecker, Jan Plock, Christian Britschgi, Lara Planas-Paz, Chantal Pauli iD

The Journal of Pathology · 2024

DOI: 10.1002/path.6282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology, 2024. Verfasst von Yanjiang Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Lamin Type A, Drug Resistance, Neoplasm, Receptor, trkA, Sarcoma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Stiftung für wissenschaftliche Forschung an der UZH/Erbschaft Bühler UZH STEB-21-003, Zürich.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Genomic rearrangements of the neurotrophic receptor tyrosine kinase genes ( NTRK1, NTRK2 , and NTRK3 ) are the most common mechanism of oncogenic activation for this family of receptors, resulting in sustained cancer cell proliferation. Several targeted therapies have been approved for tumours harbouring NTRK fusions and a new generation of TRK inhibitors has already been developed due to acquired resistance. We established a patient‐derived LMNA :: NTRK1 ‐rearranged soft‐tissue sarcoma cell model ex vivo with an acquired resistance to targeted TRK inhibition. Molecular profiling of the resistant clones revealed an acquired NF2 loss of function mutation that was absent in the parental cell model. Parental cells showed continuous sensitivity to TRK‐targeted treatment, whereas the resistant clones were insensitive. Furthermore, resistant clones showed upregulation of the MAPK and mTOR/AKT pathways in the gene expression based on RNA sequencing data and increased sensitivity to MEK and mTOR inhibitor therapy. Drug synergy was seen using trametinib and rapamycin in combination with entrectinib. Medium‐throughput drug screening further identified small compounds as potential drug candidates to overcome resistance as monotherapy or in combination with entrectinib. In summary, we developed a comprehensive model of drug resistance in an LMNA :: NTRK1 ‐rearranged soft‐tissue sarcoma and have broadened the understanding of acquired drug resistance to targeted TRK therapy. Furthermore, we identified drug combinations and small compounds to overcome acquired drug resistance and potentially guide patient care in a functional precision oncology setting. © 2024 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lamin Type ADrug Resistance, NeoplasmReceptor, trkASarcomaProtein Kinase InhibitorsMutationNeurofibromin 2Gene RearrangementHumansPyridonesBenzamidesPyrimidinonesSirolimusSoft Tissue NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsSignal TransductionDrug SynergismIndazoles

Stichwörter der Autor:innen

LMNA::NTRK1‐rearranged soft‐tissue sarcomaTRK inhibitoracquired drug resistanceex vivo sarcoma cell modeltargeted therapy

Substanzen

Lamin Type AReceptor, trkALMNA protein, humanProtein Kinase InhibitorsNF2 protein, humantrametinibNTRK1 protein, humanNeurofibromin 2entrectinibPyridones

Autor:innen und Institutionen

  • Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland.
  • Department of Plastic Surgery and Hand Surgery, Kantonsspital Aarau, Aarau, Switzerland.
  • Department of Plastic Surgery and Hand Surgery, University Hospital Zurich, Zurich, Switzerland.
  • Department of Hematology and Oncology, University Hospital Zurich, Zurich, Switzerland.
  • Medical Faculty, University of Zurich, Zurich, Switzerland.

ORCID-Profile: Chantal Pauli

Förderung

  • Stiftung für wissenschaftliche Forschung an der UZH/Erbschaft Bühler UZH STEB-21-003, Zürich

Zitieren

APA

Chen, Y., Steiner, S., Hagedorn, C., Kollar, S., Pliego-Mendieta, A., Haberecker, M., Plock, J., Britschgi, C., Planas-Paz, L., & Pauli, C. (2024). Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA :: NTRK1‐ rearranged soft‐tissue sarcoma cell model. The Journal of Pathology. https://doi.org/10.1002/path.6282

Vancouver

Chen Y, Steiner S, Hagedorn C, Kollar S, Pliego-Mendieta A, Haberecker M, et al. Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA :: NTRK1‐ rearranged soft‐tissue sarcoma cell model. The Journal of Pathology. 2024. doi:10.1002/path.6282

BibTeX
@article{Chen2024,
  author = {Chen, Yanjiang and Steiner, Sabrina and Hagedorn, Catherine and Kollar, Sarah and Pliego-Mendieta, Alicia and Haberecker, Martina and Plock, Jan and Britschgi, Christian and Planas-Paz, Lara and Pauli, Chantal},
  title = {Acquired NF2 mutation confers resistance to TRK inhibition in an ex vivo LMNA :: NTRK1‐ rearranged soft‐tissue sarcoma cell model},
  journal = {The Journal of Pathology},
  year = {2024},
  doi = {10.1002/path.6282}
}
Kostenlos starten →